PSM retrospective 41,608 patients in the USA, 1,072 treated with ivermectin and 40,536 treated with remdesivir, showing lower mortality with ivermectin treatment.
This study was presented at a conference (IMED 2021). Submissions were peer-reviewed. The treatment/control group sizes align with the estimated percentage of hospitals that used ivermectin vs. remdesivir. Hospitals in the USA receive financial incentives to use remdesivir.
Note that the authors are in a unfortunate position where they have to choose between their careers and supporting the efficacy of ivermectin. In the USA, physicians may be fired, lose their license, and become unemployable in similar positions if they accurately describe ivermectin research.
Authors do not plan to submit to a journal, providing further evidence of a negative publication bias for ivermectin research.
risk of death, 69.2% lower, OR 0.31, p < 0.001, treatment 1,072, control 40,536, propensity score matching, RR approximated with OR.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Efimenko et al., 2/28/2022, retrospective, propensity score matching, USA, North America, peer-reviewed, 6 authors, study period 1 January, 2020 - 11 July, 2021, dosage not specified, this trial compares with another treatment - results may be better when compared to placebo.